- The Daily Trade
- Posts
- Market Moves: Navigating Recovery Amidst Trump's Impact and Key Earnings Ahead
Market Moves: Navigating Recovery Amidst Trump's Impact and Key Earnings Ahead

The Daily Trade delivers sharp, daily insights on the US stock market.
Start your day with a quick look at top market news, then dive into our technical analysis of over 10,000 stocks to uncover overbought and oversold opportunities.
Stay informed, spot trends, and trade with confidence— no fluff, just actionable intel.

RSI Sell | MFI Sell | WillR Sell | AO Sell |
CCI Sell | BBANDS Sell | ULTOSC Sell | STOCH Sell |
Bloom Energy shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The latest investor updates on stocks that are trending on Monday.

RSI Buy | MFI Buy | WillR Buy | AO Buy |
CCI Buy | BBANDS Hold | ULTOSC Buy | STOCH Buy |
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

RSI Buy | MFI Hold | WillR Buy | AO Buy |
CCI Buy | BBANDS Buy | ULTOSC Buy | STOCH Buy |
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual without a sharp increase in the near future. The analyst remarked that the physician feedback and expert opinions indicate this slow pace will continue. Leqembi’s third-quarter global in-market sales were approximately $67 million, including U.S. in-market sales of approximately $39 million. Although investors ar
Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

RSI Buy | MFI Buy | WillR Buy | AO Buy |
CCI Buy | BBANDS Hold | ULTOSC Buy | STOCH Buy |
We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at where ICON Public Limited Company (NASDAQ:ICLR) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly optimistic about US equities. Its portfolio managers opine […]
ICON Public Limited Company ( NASDAQ:ICLR ) saw significant share price movement during recent months on the NASDAQGS...

RSI Buy | MFI Buy | WillR Buy | AO Buy |
CCI Buy | BBANDS Hold | ULTOSC Buy | STOCH Buy |
Unraveling the Financial Fabric and Strategic Directions of Lineage Inc
NOVI, Mich., November 06, 2024--Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world’s largest global temperature-controlled warehouse REIT, today announced its financial results for the third quarter of 2024.

RSI Buy | MFI Buy | WillR Buy | AO Buy |
CCI Buy | BBANDS Buy | ULTOSC Hold | STOCH Buy |
Conagra Brands, Inc. (NYSE: CAG) today announced that it has been recognized on the 2024 Best for Vets: Employers list by Military Times. This recognition comes as the company continues to demonstrate its dedication to supporting veterans and active-duty service members, as well as their families, through strategic partnerships and internal initiatives.
Key Insights Given the large stake in the stock by institutions, Conagra Brands' stock price might be vulnerable to...
We want to hear from YOU!

Your feedback is important to us. We’re always looking for ways to improve and would love to hear your thoughts on how we can make this newsletter even better for you. Whether you have suggestions, ideas, or just want to share what you enjoy most, we’re all ears.
Simply reply to this email with your thoughts. Every comment helps us serve you better.
Thank you for being a valued reader.
How would you rate today's newsletter?If there's anything I can do better, please let me know so I can make improvements! |
Technical Indicator Information
Relative Strength Index (RSI) | Period: 14 days | Overvalued threshold: 70 | Undervalued threshold: 30
Money Flow Index (MFI) | Period: 14 days | Overvalued threshold: 80 | Undervalued threshold: 20
Williams Percent Range (WillR) | Period: 14 days | Overvalued threshold: -20 | Undervalued threshold: -80
Aroon Oscillator (AO) | Period: 14 days | Overvalued threshold: 75 | Undervalued threshold: -75
Moving Average Convergence/Divergence (MACD) | Period: 26/12/9 days | Overvalued threshold: MACD crosses below MACD Signal | Undervalued threshold: MACD crosses above MACD Signal
Stochastic Oscillator (STOCH) | Period: 14/3/3 days | Overvalued threshold: %K crosses below %D above 80 | Undervalued threshold: %K crosses above %D below 20
Commodity Channel Index (CCI) | Period: 20 days | Overvalued threshold: 100 | Undervalued threshold: -100
Bollinger Bands (BBANDS) | Period: 20 days | Overvalued threshold: price >= upper band | Undervalued threshold: price <= lower band
Parabolic Stop and Reverse (SAR) | Period: variable 50 - 100 days | Overvalued threshold: SAR crosses above price | Undervalued threshold: SAR crosses below price
Triple Exponential Average (TRIX) | Period: 15 days | Overvalued threshold: TRIX crosses below 0 | Undervalued threshold: TRIX crosses above 0
Ultimate Oscillator (ULTOSC) | Period: 28/14/7 days | Overvalued threshold: 70 | Undervalued threshold: 30
Directional Movement Index (DMI) | Period: 14 days | Overvalued threshold: PlusDI crosses below MinusDI | Undervalued threshold: PlusDI crosses above MinusDI
Average Directional Index (ADX) | Period: variable 14 days | Requirement: >= 25
Analysis is only performed on securities with market caps in excess of $100 million and with daily trade volume in excess of $50 million.
Disclaimers
The information in our newsletter is not intended to constitute investment advice and is not designed to meet your personal financial situation. It is provided for information purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor or a group of investors. It should not be assumed that any investments in securities, companies, sectors or markets identified and described will be profitable. We strongly advise you to discuss your investment options with your financial advisor prior to making any investments, including whether any investment is suitable for your specific needs.
Although we obtain information contained in our newsletter from sources we believe to be reliable, we cannot guarantee its accuracy. The analysis provided in this newsletter is based on the prior trading day’s closing prices and may not reflect after-hours trading, earnings announcements, or other significant market events that occur outside regular trading hours. As such, any data or commentary may not fully capture the latest market movements or emerging factors. For the most current and comprehensive view, please consider additional sources or consult with a qualified financial professional.
The information provided in our newsletter is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. We reserve all rights to the content of this newsletter. Forwarding, copying, disseminating, or distributing this newsletter in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.